Transaction DateRecipientSharesTypePriceValue
16th February 2021Stephen Gordon10,000Exercise of derivative$0.67$6,700.00
16th February 2021Stephen Gordon10,000Open or private sale$31.33$313,300.00
9th February 2021Capital Management, L.P. Abrams786,664Open or private sale$33.32$26,208,733.82
9th February 2021John F Sullivan200Open or private sale$34.18$6,836.00
9th February 2021John F Sullivan8,600Exercise of derivative$0.28$2,408.00
9th February 2021John F Sullivan8,400Open or private sale$32.78$275,352.00
8th February 2021Ventures Fund Iv General Partner Llc Flagship71,667Open or private purchase$11.50$824,170.50
8th February 2021Ventures Fund Iv General Partner Llc Flagship71,667Open or private purchase$11.50$824,170.50
8th February 2021Ventures Fund Iv General Partner Llc Flagship71,666Open or private purchase$11.50$824,159.00
8th February 2021Capital Management, L.P. Abrams88,483Open or private sale$26.24$2,321,705.44
Trans Medics Group
Trans Medics Group logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 8/10.


TransMedics Group, Inc. focuses on the preservation of human organs for transplant in a near-physiologic condition. The company was founded by Waleed H. Hassanein in October 2018.


Ticker: TMDX
Sector: Health Technology
Industry: Medical Specialties
SEC Central Index Key (CIK): 1756262
Employees: 109
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Fundamentals